Navigation Links
Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint

pany headquartered in Mountain View, California. Scios is developing novel treatments for cardiovascular disease. The company's disease- based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small molecule compounds and peptides for markets with unmet medical needs. For more information, visit www.sciosinc.com.

IMPORTANT SAFETY INFORMATION

HYPOTENSION

NATRECOR(R) (nesiritide) may cause hypotension and should be administered only in settings where blood pressure can be monitored closely. If hypotension occurs during administration of NATRECOR(R) the dose should be reduced or discontinued. At the recommended dose of NATRECOR(R), the incidence of symptomatic hypotension (4%) was similar to that of IV nitroglycerin (5%). Asymptomatic hypotension occurred in 8% of patients treated with either drug. In some cases, hypotension that occurs with NATRECOR(R) may be prolonged. The mean duration of symptomatic hypotension was longer with NATRECOR(R) than IV nitroglycerin (2.2 versus 0.7 hours, respectively). NATRECOR(R) should not be used in patients with systolic blood pressure <90 mm Hg or as primary therapy in patients with cardiogenic shock. The rate of symptomatic hypotension may be increased with a baseline blood pressure <100 mm Hg, and NATRECOR(R) should be used cautiously in these patients. In earlier trials, when NATRECOR(R) was initiated at doses higher than the 2 mcg/kg bolus followed by a 0.010 mcg/kg/min infusion, the frequency, duration, and intensity of hypotension was increased. The hypotensive episodes were also more often symptomatic and/or more likely to require medical intervention. NATRECOR(R) is not recommended for patients for whom vasodilating agents are not appropriate and should be avoided in patients with low cardiac filling pressures.

RENAL

NATRECOR(R) may af
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/7/2009)... Fla., Nov. 7 Most patients with h... that signal an oncoming HAE attack giving the pat...crease the morbidity associated with that attack, ...e 2009 American College of Allergy, Asthma & I...n of symptoms such as fatigue and nausea, which oc...
(Date:11/6/2009)...Mass., Nov. 6 DUSA Pharm...atology company that is developing and marketing L...r products focused on patients with common skin co...Chief Executive Officer, will present a corporate ...it 2009 on Tuesday, November 10, 2009 at 10:00 a.m...
(Date:11/6/2009)...a., Nov. 6 Roper Indust...has signed a definitive agreement to acquire Verat...al devices. The Verathon Board of Directors has a... to customary regulatory approvals and closing con...ies expect the closing to be completed in early De...
Breaking Medicine Technology:Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 1House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 2American Medical Association Passes Resolution Supporting Sustainable Food System 49307 1American Medical Association Passes Resolution Supporting Sustainable Food System 49307 2American Medical Association Passes Resolution Supporting Sustainable Food System 49307 3Promising biomarker and candidate tumor suppressor gene identified for colorectal cancer 49304 1Promising biomarker and candidate tumor suppressor gene identified for colorectal cancer 49304 2
.... 8 Johnson & Johnson Pharmaceutical,Research & D...Phase III,trial that showed that investigational a...e 86% of patients with diabetic foot infections --...hicillin-resistant Staphylococcus,aureus (MRSA). ...ng of the Infectious,Disease Society of America (I...
...t and Selective MEK inhibitor with Favorable In Vi...erties -, CARLSBAD, Calif., Oct. 8 Ardea Bioscie...n the discovery and,development of small-molecule ...cancer and inflammatory diseases, today announced ...DEA119, will be presented at,the American Associat...
Other Medicine Technology:New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 2New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 3New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 4Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 3
(Date:11/8/2009)...lth holds open house at Victoria campus , ...2009 -- UCW Academy of Health invites anyone looki...ealth care industry to attend their open house in ...Academy of Health, which offers diplomas in areas ...s, designs its programs to meet the needs of the h...
(Date:11/8/2009)...ire/ -- Speaker Nancy Pelosi and Democratic leader...age of H.R. 3962, the Affordable Health Care for A...15. Below are the Speaker,s opening remarks: ,...ll from the President of the United States, Barack...he American people. I thank the President for his ...
(Date:11/8/2009)...s is pleased to announce that it has been successf...ound who recently received an award on the $800 mi...ncludes not only the Veterans Administration, but ...gencies. , New York, NY (...pleased to announce that it has been successful in...
(Date:11/8/2009)... in the Western District of Pennsylvania award a F...ng for a medical malpractice case. Attorneys Thom...mas E. Crenney and Associates, LLC handled the cas... against the Uniontown Hospital. The woman had to... age 18. , Pittsburgh, PA...
(Date:11/8/2009)...health advocates committed to achieving meaningful.... 7 "Tonight the U.S. H... voice of America,s families by passing the Afford...ust deliver, without delay, on the promise of mean...do, President and CEO of the National Alliance for...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2
...t is important that older people escape falls, bec...s people age, they are more likely to have a fall ...ine in general health. And since an older person's...you can to avoid a fall. A balanced diet with at l...
...n amino-acid taste receptor.Dr Charles S. Zuker, f...iversity of California, San Diego, reports his tea...entify five different tastes — bitter, salty, sour... researchers ten years ago.// In opposition t...
...educe high blood pressure in rats who had kidney f...nd that rats with impaired kidneys// and high bloo... radicals. This process, known as oxidative stress...uces the high blood pressure. The vitamin seem...
...owed Biolase Technology of San Clemente, in Califo... for root canal procedures on hard and soft tissue...laser root canal and covers all enamel, dentin and...nd the water particles themselves provide the cutt...
...ed the drug, Gleevec, for the treatment of chronic...ts about 4,500 people in the USA each year. A stud... this kind of cancer, which, although cases are ra...nts to live longer than expected. Experts say the ...
...ifosa) was initially lauded as a major breakthroug...red that patients often stopped their// prescripti...: It was supposed to be taken upon waking 30 minut...dose at once, enrolling 1200 postmenopausal women ...
Other Medicine News:Health News:Comprehension of taste receptor, 2
CRP Calibrator Series (Multi-point, Liquid)
Fructosamine Control Level 1
Immunoassay Control Level 3
Urine Precision Control Level 2
Medicine Products: